Abstract
Management of stage III non-small cell lung cancers is based on concomitant chemo-radiotherapy for most of the cases. During these last years, the main advance was the utilization of one-year adjuvant Durvalumab, leading to a 10% increase in overall survival. Even if major technological advances have been made in radiotherapy, no clinical benefit was observed in relation with this technique. Particularly, dose escalation did not improve overall survival or local control. Some explanations have been proposed as an insufficient systemic treatment or an increase in cardiac toxicity. Sparing of noninvolved lymph nodes areas from the radiation fields is an important goal at the time of immunotherapy. Current trials try to increase the dose on a limited volume, defined on a TEP-Scan performed before or during radiotherapy. Post-operative radiotherapy did not demonstrate any improvement in survival, even in case of mediastinal lymph node involvement.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
